DDInter1086 DDInter1676
An alkylating agent of value against both hematologic malignancies and solid tumors.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Lomustine {u} (Compound) treats {v} (Disease) brain cancer
Lomustine {u} (Compound) binds {v} (Gene) CYP3A4
Lomustine {u} (Compound) is included by {v} (Pharmacologic Class) Alkylating Activity
Lomustine {u} (Compound) causes {v} (Side Effect) Visual impairment
Lomustine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Moxifloxacin
Lomustine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Delafloxacin
Lomustine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Filgrastim
Lomustine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Radium Ra 223 dichloride
Lomustine {u} may lead to a major life threatening interaction when taken with {v} Lomitapide
Lomustine {u} may lead to a major life threatening interaction when taken with {v} Clozapine
Lomustine (Compound) treats brain cancer (Disease)
Lomustine (Compound) binds CYP3A4 (Gene)
Lomustine (Compound) is included by Alkylating Activity (Pharmacologic Class)
Lomustine (Compound) causes Visual impairment (Side Effect)
Lomustine may cause a minor interaction that can limit clinical effects when taken with Moxifloxacin
Lomustine may cause a minor interaction that can limit clinical effects when taken with Delafloxacin
Lomustine may cause a moderate interaction that could exacerbate diseases when taken with Filgrastim
Lomustine may cause a moderate interaction that could exacerbate diseases when taken with Radium Ra 223 dichloride
Lomustine may lead to a major life threatening interaction when taken with Lomitapide
Lomustine may lead to a major life threatening interaction when taken with Clozapine